CN108143975A - 一种治疗小儿积食的中药组合物、组合物制剂及制备方法 - Google Patents
一种治疗小儿积食的中药组合物、组合物制剂及制备方法 Download PDFInfo
- Publication number
- CN108143975A CN108143975A CN201810164661.6A CN201810164661A CN108143975A CN 108143975 A CN108143975 A CN 108143975A CN 201810164661 A CN201810164661 A CN 201810164661A CN 108143975 A CN108143975 A CN 108143975A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- indigestion
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 201000006549 dyspepsia Diseases 0.000 title claims abstract description 65
- 239000002131 composite material Substances 0.000 title claims abstract description 37
- 239000003124 biologic agent Substances 0.000 claims abstract description 37
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 30
- 241000287828 Gallus gallus Species 0.000 claims abstract description 10
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 10
- 210000004317 gizzard Anatomy 0.000 claims abstract description 10
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 235000008671 Calycanthus floridus Nutrition 0.000 claims abstract description 9
- 235000008670 Calycanthus occidentalis Nutrition 0.000 claims abstract description 9
- 244000268590 Euryale ferox Species 0.000 claims abstract description 9
- 244000148992 Lindera benzoin Species 0.000 claims abstract description 9
- 235000004520 Lindera benzoin Nutrition 0.000 claims abstract description 9
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 claims abstract description 9
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 9
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 9
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 9
- 239000010271 massa medicata fermentata Substances 0.000 claims abstract description 9
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 8
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 8
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 8
- 240000008154 Piper betle Species 0.000 claims abstract description 3
- 235000008180 Piper betle Nutrition 0.000 claims abstract description 3
- 244000088415 Raphanus sativus Species 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 46
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 36
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 34
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 235000019156 vitamin B Nutrition 0.000 claims description 28
- 239000011720 vitamin B Substances 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 22
- 229940046001 vitamin b complex Drugs 0.000 claims description 22
- GIPOFCXYHMWROH-UHFFFAOYSA-L 2-aminoacetate;iron(2+) Chemical compound [Fe+2].NCC([O-])=O.NCC([O-])=O GIPOFCXYHMWROH-UHFFFAOYSA-L 0.000 claims description 19
- 229940086413 ferrous bisglycinate Drugs 0.000 claims description 19
- 235000011649 selenium Nutrition 0.000 claims description 19
- 229940088594 vitamin Drugs 0.000 claims description 19
- 229930003231 vitamin Natural products 0.000 claims description 19
- 235000013343 vitamin Nutrition 0.000 claims description 19
- 239000011782 vitamin Substances 0.000 claims description 19
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 19
- 235000016804 zinc Nutrition 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 17
- 239000000395 magnesium oxide Substances 0.000 claims description 17
- 229910052711 selenium Inorganic materials 0.000 claims description 17
- 239000011669 selenium Substances 0.000 claims description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 16
- 229930003268 Vitamin C Natural products 0.000 claims description 16
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 16
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical class [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 16
- 235000011086 calcium lactate Nutrition 0.000 claims description 16
- 239000013522 chelant Substances 0.000 claims description 16
- 239000012153 distilled water Substances 0.000 claims description 16
- 239000011718 vitamin C Substances 0.000 claims description 16
- 235000019154 vitamin C Nutrition 0.000 claims description 16
- 239000011701 zinc Substances 0.000 claims description 16
- 229910052725 zinc Inorganic materials 0.000 claims description 16
- 239000004367 Lipase Substances 0.000 claims description 13
- 102000004882 Lipase Human genes 0.000 claims description 13
- 108090001060 Lipase Proteins 0.000 claims description 13
- 239000001527 calcium lactate Substances 0.000 claims description 13
- 229960002401 calcium lactate Drugs 0.000 claims description 13
- 235000019421 lipase Nutrition 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 239000004382 Amylase Substances 0.000 claims description 10
- 102000013142 Amylases Human genes 0.000 claims description 10
- 108010065511 Amylases Proteins 0.000 claims description 10
- 235000019418 amylase Nutrition 0.000 claims description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 9
- 239000011975 tartaric acid Substances 0.000 claims description 9
- 235000002906 tartaric acid Nutrition 0.000 claims description 9
- 241001608472 Bifidobacterium longum Species 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 8
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 7
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 5
- 229930003270 Vitamin B Natural products 0.000 claims description 5
- 229960005069 calcium Drugs 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 235000001465 calcium Nutrition 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 229930003537 Vitamin B3 Natural products 0.000 claims description 2
- 229930003571 Vitamin B5 Natural products 0.000 claims description 2
- 229930003761 Vitamin B9 Natural products 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims description 2
- 235000019160 vitamin B3 Nutrition 0.000 claims description 2
- 239000011708 vitamin B3 Substances 0.000 claims description 2
- 239000011675 vitamin B5 Substances 0.000 claims description 2
- 235000009492 vitamin B5 Nutrition 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000021468 vitamin B8 Nutrition 0.000 claims description 2
- 235000019159 vitamin B9 Nutrition 0.000 claims description 2
- 239000011727 vitamin B9 Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- 229930003471 Vitamin B2 Natural products 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 21
- 235000013305 food Nutrition 0.000 abstract description 17
- 210000000952 spleen Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract description 8
- 206010067171 Regurgitation Diseases 0.000 abstract description 8
- 208000004998 Abdominal Pain Diseases 0.000 abstract description 7
- 206010059186 Early satiety Diseases 0.000 abstract description 7
- 102000016267 Leptin Human genes 0.000 abstract description 7
- 108010092277 Leptin Proteins 0.000 abstract description 7
- 206010047700 Vomiting Diseases 0.000 abstract description 7
- 238000009825 accumulation Methods 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 7
- 229940039781 leptin Drugs 0.000 abstract description 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 229940088597 hormone Drugs 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 206010000060 Abdominal distension Diseases 0.000 abstract description 4
- 230000000202 analgesic effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 21
- 210000002784 stomach Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 9
- 241000220259 Raphanus Species 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000005611 electricity Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 108090000783 Renin Proteins 0.000 description 6
- 102100028255 Renin Human genes 0.000 description 6
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 5
- 101800001586 Ghrelin Proteins 0.000 description 5
- 108010088847 Peptide YY Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000001079 digestive effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 231100001274 therapeutic index Toxicity 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000030136 gastric emptying Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 240000006432 Carica papaya Species 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 102100029909 Peptide YY Human genes 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 210000003165 abomasum Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/23—Aspartic endopeptidases (3.4.23)
- C12Y304/23004—Chymosin (3.4.23.4), i.e. rennin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种治疗小儿积食的中药组合物,包括以下重量份组分:4‑7份炒山楂、3‑8份炒麦芽、1‑3份炒神曲、4‑7份鸡内金、1‑3份莱菔子、10‑20份茯苓、2‑4份芡实、4‑8份莲子、4‑8份山药、2‑4份槟榔和2‑4份乌药。以健脾消积食,行气下气止痛为主方,显著改善小儿积食症状。本发明包含所述中药组合物、生物制剂以及营养补充剂的组合物制剂,从中医理论角度出发,健脾消积食,有效改善腹痛、腹胀、食少早饱、嗳气反酸和恶心呕吐的症状;所述组合物制剂对促进食欲的饥饿激素Ghrelin、饱食激素PYY和Leptin有显著的调节作用,改善食少早饱的症状,所述组合物制剂针对小儿积食的治愈率达95%以上。
Description
技术领域
本发明属于医药技术领域,具体涉及一种治疗小儿积食的中药组合物、组合物制剂及其制备方法。
背景技术
小儿积食是指小儿因内伤乳食、停滞不化、气滞不行、损伤脾胃,使乳食滞于中焦所形成的一种消化***功能紊乱的综合征。中医认为,幼儿“肝常有余,脾常不足”,小儿新成,代谢功能旺盛,对水谷精微的需求非常迫切,脾主运化水谷精微为气血生化之源,因此小儿快速的生长需要足够的脾胃运化才能与其相协调,但是小儿脾胃较弱,结构发育未完全运化,就形成了机体对脾的需求过大,造成“脾常不足”的不协调状态,一旦生活中饮食稍有不节制,便容易损伤脾胃而患病。中医治疗积食将症型分为“脾虚气滞”、“肝胃不和”、“脾胃湿热”和“寒热错杂”五种,但是由于患儿的体质差异和各家对该病的认识和经验不同,临床中辩证分型出现多样性。
从西医的角度,积食的概念近似于功能性消化不良(functional dysperpsia,FD),是一组以反复发作的餐后饱胀、早饱、厌食、嗳气、恶心、呕吐、上腹痛、上腹烧灼感或反感。虽然国内外对此症已有近二十年的广泛和深入研究,但是功能性消化不良的病因及其病例生理机制未完全清楚,近年来人们发现,幽门螺旋杆菌感染(Helicobacter pylori,Hp)、胃肠激素和炎症反应在其发病过程中起着重要作用。西医治疗FD的主流药物,包括促胃肠动力药、抗感染治疗、抑制胃酸分泌药、胃粘膜保护药、抗酸剂、饮食和精神治疗等。总体来说,抑酸药以及促动力药的使用是目前比较公认的常用治疗方法。
但是,目前常用的中西医治疗小儿积食的方案中,存在以下问题:
(1)中医药治疗小儿积食临床研究大多停留在经验总结上,辨证分型标准不统一、疗效评定标准不规范,许多资料与资料间缺乏可比性;
(2)在一项1034例FD儿童的流行病学研究中,Hp的感染率为27.3%2,而在成人中,功能性消化不良患者的胃粘膜内Hp检出率在40%~70%之间,即Hp在FD发病机制中起到较为重要的作用,而目前中医药治疗小儿积食的各文献配方,缺乏对Hp对FD致病的重视;
(3)目前西医治疗方案关注于缓解症状,短期能快速缓解病症的不适,但复发率高;
有研究发现,小儿功能性消化不良常伴随着营养不良状态,严重影响小儿的饮食和身体状况,甚至影响小儿的生活质量和智力发育。采用营养状况和风险筛查工具评估临床上消化不良患儿中,接受营养支持能减少住院时间和减少不良反应发生率,而目前治疗配方中,缺乏对这一方面的关注。
发明内容
基于以上问题,本发明的其一目的是提供一种有效治疗小儿积食的中药组合物。
其二目的是结合中医药治疗小儿积食的经验,提供一种针对小儿积食的潜在病因及造成的不良影响予以缓解和治疗的组合物制剂。
再一目的是提供一种所述组合物制剂的制备方法。
本发明的技术方案为:
本发明提供一种治疗小儿积食的中药组合物,包括以下重量份组分:4-7份炒山楂、3-8份炒麦芽、1-3份炒神曲、4-7份鸡内金、1-3份莱菔子、10-20份茯苓、2-4份芡实、4-8份莲子、4-8份山药、2-4份槟榔和2-4份乌药。
本发明的组合物制剂中药组分部分以健脾消积食,行气下气止痛为主方:茯苓、芡实、莲子和山药配伍,具有健脾、补肺、清热、渗温的功能,以解决幼儿因脾胃消化功能紊乱造成的营养吸收不良;配以炒山楂、炒麦芽和炒神曲,化肉食和面食,与鸡内金和莱菔子一起协同作用加强功效,不止可以化一般积食,对于积食咳嗽或难以消化停滞的食物,鸡内金都可以起到消难消停滞之积食的作用,莱菔子又可化痰、消积食;再以槟榔、乌药配合,行气止痛,解决积食幼儿经常脘腹胀痛的病症。
本发明还提供一种治疗小儿积食的组合物制剂,包括所述的中药组合物和生物制剂,所述生物制剂包括3-7份保加利亚乳杆菌、3-7份长双歧杆菌、3-7份嗜酸乳杆菌、1-3份凝乳酶、1-2份淀粉酶和1-2份脂肪酶。
本发明还提供一种治疗小儿积食的组合物制剂,包括所述的中药组合物和营养补充剂,所述营养补充剂包括0.3-0.6份维生素B群、0.3-0.6份维生素C、0.4-1.5份乳酸钙、0.3-0.6份甘氨酸亚铁、0.1-0.3份酵母锌、0.1-0.3份酵母硒和2-4份氧化镁。
本发明还提供一种治疗小儿积食的组合物制剂,包括所述的中药组合物、生物制剂和营养补充剂,所述生物制剂包括3-7份保加利亚乳杆菌、3-7份长双歧杆菌、3-7份嗜酸乳杆菌、1-3份凝乳酶、1-2份淀粉酶和1-2份脂肪酶,所述营养补充剂包括0.3-0.6份维生素B群、0.3-0.6份维生素C、0.4-1.5份乳酸钙、0.3-0.6份甘氨酸亚铁、0.1-0.3份酵母锌、0.1-0.3份酵母硒和2-4份氧化镁。
以上所述治疗小儿积食的组合物制剂,还包括辅料,所述辅料包括10-15份麦芽糊精和0.1-0.2份酒石酸。
以上所述治疗小儿积食的组合物制剂,所述维生素B群中包含维生素B1、维生素B2、维生素B3、维生素B5、维生素B6、维生素B8、维生素B9和维生素B12。
本发明提供所述的中药组合物的制备方法,包括以下步骤:
(1)将各组分混合均匀,并破碎,得到混合物颗粒,然后加入蒸馏水,并超声处理,得混合液;
(2)将步骤(1)处理后的混合液煮沸,得到煎液,过滤浓缩成在50-60℃时相对密度为1.2-1.4的稠膏,然后冻干并粉碎,得到中药药粉。
本发明的中药组合物的制备方法,在步骤(1)中,混合物颗粒与蒸馏水的比例为1:4-5;在步骤(2)中,冻干温度和压力分别为零下50-零下60℃和90-100mmHg。
本发明的中药组合物的制备方法,在步骤(1)中,破碎后的混合物颗粒粒径为15-20目,超声处理的频率为40kHz,时间为20-30min。在步骤(2)中,煮沸次数为3-4次,每次1-2小时,将每次煮沸后的煎液合并过滤,再浓缩成稠膏。
本发明提供所述治疗小儿积食的组合物制剂的制备方法,包括以下步骤:
(1)制备中药药粉:将中药组合物的各组分混合、破碎,加水蒸馏水,煮沸,得到煎液,浓缩成在50-60℃时相对密度为1.2-1.4的稠膏,冻干并粉碎,得到中药药粉;
(2)制备生物制剂混合物:将生物制剂各组分混合均匀,得到生物制剂混合物;
(3)制备营养补充剂:将维生素B群、甘氨酸亚铁、维生素C、乳酸钙、酵母锌、酵母硒和氧化镁分别进行破碎;在5-10℃下,将维生素B群的各维生素B组分溶于水中混合,然后干燥;将维生素C、甘氨酸亚铁、乳酸钙、酵母锌、酵母硒和氧化镁、麦芽糊精和酒石酸加入至乙醇溶液中搅拌至出现颗粒,干燥;将干燥后的组分混合,得到营养补充剂;
(4)将步骤(1)、(2)、(3)得到的中药药粉、生物制剂混合物以及营养补充剂混合,即得所述治疗小儿积食的组合物制剂。
本发明的治疗小儿积食的组合物制剂的制备方法,步骤(3)中的干燥条件为,60-65℃干燥15-20min。
本发明的治疗小儿积食的组合物制剂的制备方法,在步骤(3)中,破碎后过100目筛。
本发明的组合物制剂中包含的生物制剂,包括益生菌和消化酶,具体包括以下组分:
保加利亚乳杆菌:德式乳杆菌的一个亚种,被广泛的应用在酸奶制作的过程当中具有调节胃肠道健康、促进消化吸收、增加免疫功能等重要的生理功能。
长双歧杆菌:具有改善免疫***紊乱导致的肠道疾病,增加粘液层厚度,抑制病原菌侵入肠道等作用。
嗜酸乳杆菌:属于乳杆菌属,革兰氏阳性杆菌,杆的末端呈圆形,主要存在小肠中,释放乳酸,乙酸和一些对有害菌起作用的抗菌素。
以上菌种中的益生菌含量不低于1×1010cfu/g,含水量不高于5%
凝乳酶:一种最早在未断奶的小牛胃中发现的天门冬氨酸蛋白酶,可专一地切割乳中κ-酪蛋白的Phe105-Met106之间的肽键,破坏酪蛋白胶束使牛奶凝结,使乳制品更易为各种消化液中的蛋白质酶所消化。复合凝乳酶绵羊第四胃黏膜总抽取物、胃蛋白酶、凝乳酶、粘多糖等生物活性成分。使用羔棉羊第四胃破碎提取的复合凝乳酶,在条件下每mg凝乳活力不低于900凝乳单位,在-51℃100mmHg条件下冻干,含水量不高于5%。
淀粉酶:水解淀粉和糖原的酶类总称,具有高效专一性,参与人体消化过程的主要为α-淀粉酶,用于水解α-1,4-糖苷键,将大分子糖类分解促进消化。采用枯草芽孢杆菌发酵精制提纯的淀粉酶,酶活不低于350U/mg,在-51℃100mmHg条件下冻干,含水量不高于5%。
脂肪酶:脂肪酶是一类重要的水解酶类,能够在水相体系中催化水解反应,能够将摄入人体的脂肪分解促进消化和吸收,本发明使用的脂肪酶来源于番木瓜Carica papaya,植物源脂肪酶相较于更为普遍的微生物源脂肪酶,在非水介质中稳定性较高,更易分离,且原材料来源充足。切割未成熟的番木瓜过失或番木瓜树茎,收集流出的乳状汁液在零下50-零下55℃、100mmHg条件下冷冻干燥。得到的冻干粉,以1:4的质量比加入100mM pH 7.5磷酸缓冲液在4℃环境中搅拌30min,10000rpm离心10min,收集沉淀物。离心分离过程重复2-3次后,将收集的沉淀在零下50-零下55℃100mmHg条件下冻干,含水量不高于5%。
积食儿童消化液分泌较少,肠胃蠕动不规律,凝乳酶、淀粉酶和脂肪酶和协助消化,形成消化道保护粘液。在以中药组分消积食行气后,益生菌和调理因积食造成的肠胃功能紊乱,同时减少幽门螺旋杆菌的定植侵入。本发明的治疗小儿积食的组合物直接添加所述生物制剂,以益生菌起到调理肠道微生物环境、减少肠道感染、减少幽门螺旋杆菌定植、促进脑肠肽激素分泌、促进饱食激素Ghrelin分泌的作用,消化酶协助将食物中的营养成分分解为便于人体吸收的小分子。
本发明的治疗小儿积食的营养补充剂中包括维生素B群、维生素C、甘氨酸亚铁、乳酸钙、酵母锌、酵母硒和氧化镁。
小儿功能性消化不良常伴随着营养不良的状态,严重影响小儿的饮食和身体状况,甚至影响小儿的生活质量和智力发育。在治疗小儿积食过程中补充营养素,可以缩短治疗周期并减少不良反应发生率。
维生素B群:是推动体内代谢,把糖、脂肪、蛋白质等转化成热量时不可缺少的物质。
维生素B群中按照重量百分比计,各成分比例为:4.21%维生素B1、5.35%维生素B2、61.18%维生素B3、22.94%维生素B5、5.35%维生素B6、0.19%维生素B8、0.76%维生素B9、0.01%维生素B12。
维生素C:具有很强的还原性,参与营养物质代谢与合成,维持免疫功能。
甘氨酸亚铁:铁补充剂,属无味易溶有机铁,易溶于水。能避免植酸对一般铁剂的吸收障碍,其吸收率约为硫酸亚铁的3-5倍,尚可促进钙、锌、硒等多种元素的吸收,可改善缺铁性贫血。
乳酸钙:补钙剂,具有促进骨骼及牙齿的钙化形成、维持神经与肌肉的正常兴奋性和降低毛细血管通透性等作用。
氧化镁:作为抑制和缓解胃酸过多的pH调节剂,同时作为抗结剂。
酒石酸:作为抗氧化剂使用。
本发明的有益效果为:
本发明提供的一种治疗小儿积食的中药组合物,以健脾消积食,行气下气止痛为主方,显著改善小儿积食症状。
本发明包含所述中药组合物、生物制剂以及营养补充剂的组合物制剂,从中医理论角度出发,健脾消积食,有效改善腹痛、腹胀、食少早饱、嗳气反酸和恶心呕吐的症状;所述组合物制剂对促进食欲的饥饿激素Ghrelin、饱食激素PYY和Leptin有显著的调节作用,改善食少早饱的症状,所述组合物制剂针对小儿积食的治愈率达95%以上。
本发明的治疗小儿积食的组合物直接的制备方法,根据中药组合物、生物制剂和营养补充剂各自的作用和活性特点,制定加工的工艺步骤,使各组分混合均匀,在治疗过程中使组合物制剂可以更好地发挥作用。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。
以下实施例以1份为1kg。
实施例1
本发明提供一种治疗小儿积食的中药组合物,包括以下重量份组分:4份炒山楂、8份炒麦芽、1份炒神曲、7份鸡内金、1份莱菔子、20份茯苓、2份芡实、8份莲子、4份山药、4份槟榔和2份乌药。
所述的中药组合物的制备方法,包括以下步骤:
(1)将各组分混合均匀,并破碎后过20目筛,得到混合物颗粒,然后加入蒸馏水,混合物颗粒与蒸馏水的比例为1:4,并以40KHz的频率超声处理30min,得混合液;
(2)将步骤(1)处理后的混合液煮沸3次,每次煮2小时,得到煎液,将每次得到的煎液合并,过滤浓缩成在60℃时相对密度为1.2的稠膏,然后在零下60℃温度下和90mmHg的压力下冻干并粉碎,得到中药药粉。
实施例2
本发明提供一种治疗小儿积食的中药组合物,包括以下重量份组分:4份炒山楂、8份炒麦芽、1份炒神曲、7份鸡内金、1份莱菔子、20份茯苓、2份芡实、8份莲子、4份山药、4份槟榔和2份乌药。
所述的中药组合物的制备方法,包括以下步骤:
(1)将各组分混合均匀,并破碎后过20目筛,得到混合物颗粒,然后加入蒸馏水,混合物颗粒与蒸馏水的比例为1:4,并以40KHz的频率超声处理30min,得混合液;
(2)将步骤(1)处理后的混合液煮沸3次,每次煮2小时,得到煎液,将每次得到的煎液合并,过滤浓缩成在60℃时相对密度为1.2的稠膏,然后在零下60℃温度下和90mmHg的压力下冻干并粉碎,得到中药药粉。
本发明的治疗小儿积食的组合物制剂,包括上述的中药组合物和生物制剂,所述生物制剂包括7份保加利亚乳杆菌、3份长双歧杆菌、7份嗜酸乳杆菌、1份凝乳酶、2份淀粉酶和1份脂肪酶。
上述组合物制剂的制备方法,包括以下步骤:(1)制备上述中药组合物的中药药粉;(2)制备生物制剂混合物:将生物制剂各组分混合均匀,得到生物制剂混合物;(3)将步骤(1)、(2)得到的中药药粉、生物制剂混合物混合,即得所述治疗小儿积食的组合物制剂。
实施例3
本发明提供一种治疗小儿积食的中药组合物,包括以下重量份组分:7份炒山楂、3份炒麦芽、3份炒神曲、4份鸡内金、3份莱菔子、10份茯苓、4份芡实、4份莲子、8份山药、2份槟榔和4份乌药。
所述的中药组合物的制备方法,包括以下步骤:
(1)将各组分混合均匀,并破碎后过15目筛,得到混合物颗粒,然后加入蒸馏水,混合物颗粒与蒸馏水的比例为1:5,并以40KHz的频率超声处理20min,得混合液;
(2)将步骤(1)处理后的混合液煮沸4次,每次煮1小时,得到煎液,将每次得到的煎液合并,过滤浓缩成在50℃时相对密度为1.4的稠膏,然后在零下50℃温度下和100mmHg的压力下冻干并粉碎,得到中药药粉。
本发明的治疗小儿积食的组合物制剂,包括上述的中药组合物和营养补充剂,所述营养补充剂包括0.3份维生素B群、0.6份维生素C、0.4份乳酸钙、0.6份甘氨酸亚铁、0.1份酵母锌、0.3份酵母硒和2份氧化镁。
上述组合物制剂的制备方法,包括以下步骤:(1)制备上述中药组合物的中药药粉;(2)制备营养补充剂:将维生素B群、甘氨酸亚铁、维生素C、乳酸钙、酵母锌、酵母硒和氧化镁分别进行破碎;然后在10℃下,将维生素B群的各维生素B组分溶于水中混合,然后60℃烘干20min;将维生素C、甘氨酸亚铁、乳酸钙、酵母锌、酵母硒和氧化镁加入至乙醇溶液中混合均匀,60℃烘干20min;将干燥后的组分混合,得到营养补充剂;(3)将步骤(1)、(2)得到的中药药粉、营养补充剂混合,即得所述治疗小儿积食的组合物制剂。
实施例4
本发明提供一种治疗小儿积食的中药组合物,包括以下重量份组分:5份炒山楂、5份炒麦芽、2份炒神曲、6份鸡内金、2份莱菔子、15份茯苓、3份芡实、5份莲子、6份山药、3份槟榔和3份乌药。
所述的中药组合物的制备方法,包括以下步骤:
(1)将各组分混合均匀,并破碎后过18目筛,得到混合物颗粒,然后加入蒸馏水,混合物颗粒与蒸馏水的比例为1:4,并以40KHz的频率超声处理25min,得混合液;
(2)将步骤(1)处理后的混合液煮沸4次,每次煮1小时,得到煎液,将每次得到的煎液合并,过滤浓缩成在55℃时相对密度为1.3的稠膏,然后在零下55℃温度下和95mmHg的压力下冻干并粉碎,得到中药药粉。
本发明的治疗小儿积食的组合物制剂,包括上述的中药组合物、生物制剂和营养补充剂,所述生物制剂包括3份保加利亚乳杆菌、7份长双歧杆菌、3份嗜酸乳杆菌、3份凝乳酶、1份淀粉酶和2份脂肪酶,所述营养补充剂包括0.6份维生素B群、0.3份维生素C、1.5份乳酸钙、0.3份甘氨酸亚铁、0.3份酵母锌、0.1份酵母硒和4份氧化镁。
上述组合物制剂的制备方法,包括以下步骤:(1)制备上述中药组合物的中药药粉;(2)制备生物制剂混合物:将生物制剂各组分混合均匀,得到生物制剂混合物;(3)制备营养补充剂:将维生素B群、甘氨酸亚铁、维生素C、乳酸钙、酵母锌、酵母硒和氧化镁分别进行破碎;在5℃下,将维生素B群的各维生素B组分溶于水中混合,然后65℃烘干15-20min;将维生素C、甘氨酸亚铁、乳酸钙、酵母锌、酵母硒和氧化镁加入至质量份数为50%的乙醇溶液中混合均匀,60℃烘干20min;将干燥后的组分混合,得到营养补充剂;(4)将步骤(1)、(2)、(3)得到的中药药粉、生物制剂混合物、营养补充剂混合,即得所述治疗小儿积食的组合物制剂。
实施例5
本发明提供一种治疗小儿积食的中药组合物,包括以下重量份组分:6份炒山楂、6份炒麦芽、3份炒神曲、6份鸡内金、3份莱菔子、15份茯苓、3份芡实、6份莲子、6份山药、3份槟榔和3份乌药。
所述的中药组合物的制备方法,包括以下步骤:
(1)将各组分混合均匀,并破碎后过20目筛,得到混合物颗粒,然后加入蒸馏水,混合物颗粒与蒸馏水的比例为1:4,并以40KHz的频率超声处理30min,得混合液;
(2)将步骤(1)处理后的混合液煮沸4次,每次煮1小时,得到煎液,将每次得到的煎液合并,过滤浓缩成在60℃时相对密度为1.2的稠膏,然后在零下51℃温度下和100mmHg的压力下冻干并粉碎,得到中药药粉。
本发明的治疗小儿积食的组合物制剂,包括上述的中药组合物、生物制剂、营养补充剂以及辅料,所述生物制剂包括6份保加利亚乳杆菌、6份长双歧杆菌、6份嗜酸乳杆菌、2份凝乳酶、1份淀粉酶和1份脂肪酶,所述营养补充剂包括0.5份维生素B群、0.5份维生素C、1份乳酸钙、0.5份甘氨酸亚铁、0.2份酵母锌、0.2份酵母硒和3份氧化镁,所述辅料包括12份麦芽糊精和0.1份酒石酸。维生素B群中按照重量百分比计,各成分比例为:4.21%维生素B1、5.35%维生素B2、61.18%维生素B3、22.94%维生素B5、5.35%维生素B6、0.19%维生素B8、0.76%维生素B9、0.01%维生素B12。
上述组合物制剂的制备方法,包括以下步骤:(1)制备上述中药组合物的中药药粉;(2)制备生物制剂混合物:将生物制剂各组分混合均匀,得到生物制剂混合物;(3)制备营养补充剂:将维生素B群、甘氨酸亚铁、维生素C、乳酸钙、酵母锌、酵母硒和氧化镁分别进行破碎;然后在10℃下,将维生素B群的各维生素B组分溶于水中混合,然后65℃烘干15-20min;将维生素C、甘氨酸亚铁、乳酸钙、酵母锌、酵母硒和氧化镁、麦芽糊精和酒石酸加入至质量份数为50%的乙醇溶液中搅拌至出现颗粒,60℃烘干15-20min;将干燥后的组分混合,得到营养补充剂;(4)将步骤(1)、(2)、(3)得到的中药药粉、生物制剂混合物、营养补充剂混合,即得所述治疗小儿积食的组合物制剂。
实施例1、2和3中可根据实际成型与防氧化需求,添加辅料,添加量在10-15份麦芽糊精和0.1-0.2份酒石酸的范围内调整。例如实施例1中可添加10份麦芽糊精和0.2份酒石酸;实施例2中可添加15份麦芽糊精和0.2份酒石酸。
实验例:
1、病例入选标准
(1)年龄3~12岁,男女不限。
(2)符合儿童功能性消化不良诊断标准,病程2个月以上,每周至少一次,并符合以下3项条件:①持续或反复发作的上腹部(脐上)疼痛或不适、早饱、嗳气、恶心、呕吐、反酸;②症状在排便后不能缓解,或症状发作与排便频率或粪便性状的改变无关(即除外肠易激综合征);③无炎症性、解剖学、代谢性或肿瘤性疾病的证据可以解释患儿的症状。
(3)符合中药新药治疗胃脘痛临床研究指导原则有关中医辨证分型的标准:主症:脘腹痞满,食后加重,食欲不振,疲乏无力;次症:恶心呕吐,大便稀溏,舌淡苔白,脉沉细。
(4)患儿监护人签署知情同意书。
2、病例排除标准
年龄不符合要求;正在使用或实验开始前4周内曾使用其他药物治疗本病;使用抗生素、糖皮质激素者;除正常饮食,额外摄取各类营养补充剂者;甲亢、高血压、心脏病、糖尿病、血液***疾病患者;肝肾功能不全的患者。
3、病例一般资料
136例功能性消化不良的儿童,男72例,女64例,年龄3~12岁,平均()岁。患儿均符合入选条件。利用随机数字表将患儿随机分为对照组和试验组,每组68例,两组患儿一般资料比较,差异无统计学意义(P>0.05),有可比性。
表1对照组与实验组病例资料
4、实验方法
对照组采用潘立酮治疗,具体方法如下:患儿口服多潘立酮0.3ml/kg,3次/d,餐前30min服用,连续服用28d为1个疗程。试验组采用本发明实施例5组合物制剂配方,具体方法如下:患儿在饭后30分钟,将3g本发明配方制剂用150ml 35℃左右的温水冲泡饮下,2次/d,连续服用28d为一个疗程。
5、疗效评价
5.1症状分级量化方法
腹痛症状:轻微腹痛,时作时止,不影响学习生活,计1分;腹痛可忍,发作频繁,影响学习生活,计2分;腹痛难忍,持续不止,常需服止痛药缓解,计3分。腹胀症状:轻微胀满,时作时止,不影响学习生活,计1分;胀满明显但可忍受,时有发作,影响学习生活,计2分;胀满难忍,持续不止,需服对症药缓解,计3分。食少症状:食量减1/4为轻度,计1分;食量减少1/3为中度,计2分;食量减少1/2为重度,计3分。嗳气反酸:偶有嗳气反酸,计1分;时有嗳气反酸,计2分;频频嗳气反酸,计3分。恶心呕吐:偶有恶心,计1分;时有恶心,偶有呕吐,计2分;频频恶心,有时呕吐,计3分。
5.2胃液体排空功能检测
采用实时超声显像对胃液体排空功能进行检测。患儿检测前1天晚8时起禁饮水,确认胃排空状态下,在2-3min内饮完标准试验餐(试验餐配置:参照首都儿科研究所试验餐配制方法,市售牛奶300ml,加蛋黄2个,加蔗糖75g,总热量1093大卡)。测定进餐后即刻胃窦部舒张面积,以后每隔30min测定全胃面积一共4次。检测中受试者活动量控制在日常水平。测量胃窦面积时采取仰卧位,于剑突下偏右纵行切面扫描,件椭圆形或圆形胃窦,以肠系膜上静脉为标志定位。测量胃窦部舒张相面积,第一次测量确定部位,以后均于该部位测量。胃窦排空率=(进食后即刻胃窦面积-检测时刻胃窦面积)/进食后即刻面积×100%。
5.3胃电图检查及评价标准
分别比较试验组和对照组患儿在治疗前和治疗后的餐前胃电指标和餐后胃电指标数据。正常胃电节律(N)为2.4~3.7次/min,胃电节律过缓(B)为小于2.4次/min,胃电节律过速(T)为大于3.7次/min。记录软件分析N、B、T百分比,以N百分比<65%为胃电节律异常。
5.4血浆中三种脑肠肽(Ghrelin、Leptin及PYY)浓度检测
在上午9~12时采集倾城静脉血2ml,注入含有10g/L EDTA 30μl和抑肽酶20μl的试管中,充分混匀,静置4小时后与2~8℃离心机中以2000r/min,离心15min,收集血浆,-70℃低温冰箱冻存,待标本集齐后同一批试剂盒检测血浆Ghrelin、Leptin和PYY水平。检测采用ELISA试剂盒(Ghrelin ELISA试剂盒由美国RD公司生产,上海易利生物科技有限公司提供;人Leptin ELISA试剂盒由上海依科赛生物制品有限公司提供;人PYYELISA试剂盒有RayBio公司提供)。
5.5疗效评价标准
疗效指数=(治疗前证候总分-治疗后证候总分)/治疗前证候总分×100%。治愈:症状、体征消失或基本消失,疗效指数≥95%;显效:临床症状、体征明显改善,疗效指数≥70%;有效:临床症状、体征均有好转,疗效指数≥30%;无效:临床症状、体征无明显改善,甚至加重,疗效指数<30%。
6安全性评价
6.1安全性观测①一般症状、体征;②血、尿、便常规检查;③心、肝、肾功能检查;以上检查指标在用药前及用药后分别监测。
6.2不良反应严重程度分级标准
轻度:受试者可忍受,不影响治疗,不需要特别处理,对受试者康复无影响;中度:受试者难以忍受,需要撤药或做特殊处理,对受试者康复有直接影响;重度:危及受试者生命,致死或致残,需立即撤药或做紧急处理。
7统计学分析
采用SPSS 19.0软件进行统计学分析,计量资料以表示,采用t检验;计数资料采用x2检验,以P<0.05为差异有统计学意义。
8结果
8.1试验组与对照组治疗前后症状评分比较
治疗前两组比较,差异无统计学意义(P<0.05)。试验组与对照组均能改善腹痛、腹胀、食少早饱、嗳气反酸、恶心等临床症状,与治疗前差异有统计学意义(P<0.05),但试验组在各项改善情况上均优于对照组(P<0.05)。
表2两组治疗前后临床评分比较(分)
8.2试验组与对照组临床疗效比较
试验组患儿总有效率为95.6%,对照组为73.5%,两组总有效率比较,差异有统计学意义(P<0.05)
表3两组患儿治疗前后症状比较[n(%)]
8.3试验组与对照组治疗前后胃电指标比较
治疗前两组胃电指标比较,差异无统计学意义(P>0.05)。两组治疗后正常胃电节律明显增加,过缓胃电节律减少,与治疗前比较,差异有统计学意义(P<0.05)。治疗后试验组与对照组比较,差异有统计学意义(P<0.05),两组在改善过速胃电节律方面无明显差异。
表4两组治疗前后胃电指标比较(%)
8.4试验组与对照组治疗前后胃窦排空率比较
治疗前两组胃排空率比较,差异无统计学意义(P>0.05)。餐后30分钟时,胃窦排空率两组治疗后差异无统计学意义(P>0.05),60分钟和90分钟排空率差异明显(P<0.01),试验组排空率明显高于对照组。
表5试验组与对照组治疗30天餐后胃窦排空率比较(%)
8.5试验组与对照组治疗前后三种脑肠肽(Ghrelin、Leptin及PYY)在血浆中浓度变化
治疗前两组三种脑肠肽比较,差异无统计学意义(P>0.05)。两组治疗后,均与治疗前有改善(差异有统计学意义,P<0.05),促进食欲的饥饿激素Ghrelin较治疗前浓度提高,而两种抑制食欲和调节能量状态的饱食激素PYY和Leptin均降低,且试验组各项指标均优于对照组(P<0.05)。
表6试验组与对照组治疗前后三种脑肠肽在血浆中浓度水平比较(ng/L)
8.6安全性评价
在试验观察期间,患儿与安全性有关的生命体征及体格检查在用药前后均在正常范围内,未发现不良反应事件。安全性评价为1级:安全,无任何不良反应。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (10)
1.一种治疗小儿积食的中药组合物,其特征在于,包括以下重量份组分:4-7份炒山楂、3-8份炒麦芽、1-3份炒神曲、4-7份鸡内金、1-3份莱菔子、10-20份茯苓、2-4份芡实、4-8份莲子、4-8份山药、2-4份槟榔和2-4份乌药。
2.一种治疗小儿积食的组合物制剂,其特征在于,包括权利要求1所述的中药组合物和生物制剂,所述生物制剂包括3-7份保加利亚乳杆菌、3-7份长双歧杆菌、3-7份嗜酸乳杆菌、1-3份凝乳酶、1-2份淀粉酶和1-2份脂肪酶。
3.一种治疗小儿积食的组合物制剂,其特征在于,包括权利要求1所述的中药组合物和营养补充剂,所述营养补充剂包括0.3-0.6份维生素B群、0.3-0.6份维生素C、0.4-1.5份乳酸钙、0.3-0.6份甘氨酸亚铁、0.1-0.3份酵母锌、0.1-0.3份酵母硒和2-4份氧化镁。
4.一种治疗小儿积食的组合物制剂,其特征在于,包括权利要求1所述的中药组合物、生物制剂和营养补充剂,所述生物制剂包括3-7份保加利亚乳杆菌、3-7份长双歧杆菌、3-7份嗜酸乳杆菌、1-3份凝乳酶、1-2份淀粉酶和1-2份脂肪酶,所述营养补充剂包括0.3-0.6份维生素B群、0.3-0.6份维生素C、0.4-1.5份乳酸钙、0.3-0.6份甘氨酸亚铁、0.1-0.3份酵母锌、0.1-0.3份酵母硒和2-4份氧化镁。
5.根据权利要求4所述的组合物制剂,其特征在于,还包括辅料,所述辅料包括10-15份麦芽糊精和0.1-0.2份酒石酸。
6.根据权利要求3或4所述的组合物制剂,其特征在于,所述维生素B群中包含维生素B1、维生素B2、维生素B3、维生素B5、维生素B6、维生素B8、维生素B9和维生素B12。
7.根据权利要求1所述的中药组合物的制备方法,其特征在于,包括以下步骤:
(1)将各组分混合均匀,并破碎,得到混合物颗粒,然后加入蒸馏水,并超声处理,得混合液;
(2)将步骤(1)处理后的混合液煮沸,得到煎液,过滤浓缩成在60℃时相对密度为1.2-1.4的稠膏,然后冻干并粉碎,得到中药药粉。
8.根据权利要求7所述的中药组合物的制备方法,其特征在于,在步骤(1)中,混合物颗粒与蒸馏水的比例为1:4-5;在步骤(2)中,冻干温度和压力分别为零下50-零下60℃和90-100mmHg。
9.根据权利要求5所述的组合物制剂的制备方法,其特征在于,包括以下步骤:
(1)制备中药药粉:将中药组合物的各组分混合、破碎,加水蒸馏水,煮沸,得到煎液,浓缩成在50-60℃时相对密度为1.2-1.4的稠膏,冻干并粉碎,得到中药药粉;
(2)制备生物制剂混合物:将生物制剂各组分混合均匀,得到生物制剂混合物;
(3)制备营养补充剂:将维生素B群、甘氨酸亚铁、维生素C、乳酸钙、酵母锌、酵母硒和氧化镁分别进行破碎;在5-10℃下,将维生素B群的各维生素B组分溶于水中混合,然后干燥;将维生素C、甘氨酸亚铁、乳酸钙、酵母锌、酵母硒和氧化镁、麦芽糊精和酒石酸加入至乙醇溶液中搅拌至出现颗粒,干燥;将干燥后的组分混合,得到营养补充剂;
(4)将步骤(1)、(2)、(3)得到的中药药粉、生物制剂混合物以及营养补充剂混合,即得所述治疗小儿积食的组合物制剂。
10.根据权利要求9所述的制备方法,其特征在于,在步骤(3)中的干燥条件为,60-65℃干燥15-20min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810164661.6A CN108143975A (zh) | 2018-02-26 | 2018-02-26 | 一种治疗小儿积食的中药组合物、组合物制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810164661.6A CN108143975A (zh) | 2018-02-26 | 2018-02-26 | 一种治疗小儿积食的中药组合物、组合物制剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108143975A true CN108143975A (zh) | 2018-06-12 |
Family
ID=62456011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810164661.6A Pending CN108143975A (zh) | 2018-02-26 | 2018-02-26 | 一种治疗小儿积食的中药组合物、组合物制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108143975A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109833354A (zh) * | 2019-03-06 | 2019-06-04 | 北京坤秋健康科技有限公司 | 一种治疗儿童积食的药物组合物及其应用 |
CN112868810A (zh) * | 2021-01-28 | 2021-06-01 | 张晓丽 | 一种中式纹理手撕鲜奶酪及加工工艺 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030008184A (ko) * | 2002-12-18 | 2003-01-24 | 김대곤 | 함초,다시마 를 주제로 한 건강식품 |
CN102579905A (zh) * | 2012-02-21 | 2012-07-18 | 张徐红 | 治疗小儿疳积的药物组合物及其用法 |
CN106110091A (zh) * | 2016-07-22 | 2016-11-16 | 胡彬 | 一种健胃消食膏及其制备方法 |
CN106889414A (zh) * | 2017-02-17 | 2017-06-27 | 汉臣氏(沈阳)儿童制品有限公司 | 双菌山楂固体饮料 |
CN107183430A (zh) * | 2017-05-31 | 2017-09-22 | 北京佑众全椒制药有限公司 | 一种可增强食欲的滁菊饮料及其制备方法 |
-
2018
- 2018-02-26 CN CN201810164661.6A patent/CN108143975A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030008184A (ko) * | 2002-12-18 | 2003-01-24 | 김대곤 | 함초,다시마 를 주제로 한 건강식품 |
CN102579905A (zh) * | 2012-02-21 | 2012-07-18 | 张徐红 | 治疗小儿疳积的药物组合物及其用法 |
CN106110091A (zh) * | 2016-07-22 | 2016-11-16 | 胡彬 | 一种健胃消食膏及其制备方法 |
CN106889414A (zh) * | 2017-02-17 | 2017-06-27 | 汉臣氏(沈阳)儿童制品有限公司 | 双菌山楂固体饮料 |
CN107183430A (zh) * | 2017-05-31 | 2017-09-22 | 北京佑众全椒制药有限公司 | 一种可增强食欲的滁菊饮料及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109833354A (zh) * | 2019-03-06 | 2019-06-04 | 北京坤秋健康科技有限公司 | 一种治疗儿童积食的药物组合物及其应用 |
CN112868810A (zh) * | 2021-01-28 | 2021-06-01 | 张晓丽 | 一种中式纹理手撕鲜奶酪及加工工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108812909B (zh) | 一种改善偏食或厌食的辅食营养补充品及其制备方法 | |
CN105995976A (zh) | 一种具有降脂减肥作用的综合酵素粉及其应用 | |
CN110338402A (zh) | 一种复合益生菌粉及其制备方法 | |
CN101700063A (zh) | 一种具有健胃作用的草本酸奶的制备方法 | |
CN106172758A (zh) | 一种可有效改善肠道微环境的酸奶及其制备方法 | |
CN1096453A (zh) | 小儿消化止泻灵 | |
CN106360420A (zh) | 一种发酵型醋蛋液的制备方法 | |
CN108935709A (zh) | 一种益生菌羊奶片及其制备方法 | |
KR100716123B1 (ko) | 마 또는 산약의 유산 발효액을 함유하는 변비 및 비만의예방 및 개선용 식품 조성물 | |
CN108882730A (zh) | 一种调节人体肠胃机能的饮品 | |
CN102742653B (zh) | 一种健脑安神益生菌羊奶片及其制备方法 | |
CN113519736A (zh) | 一种肠道健康调理食品及其制备方法和应用 | |
CN106047631A (zh) | 一种通过酶解制备的草莓醋及其应用 | |
CN108143975A (zh) | 一种治疗小儿积食的中药组合物、组合物制剂及制备方法 | |
CN107334156A (zh) | 催乳全营养配方食品 | |
CN112425658A (zh) | 一种牛初乳制品及其制备方法和应用 | |
CN115777931A (zh) | 一种调理肠胃的膳食补充剂及其制备方法与应用 | |
US11969447B2 (en) | Use of spray-dried powder derived from lactic acid bacterial strains and herbal extracts for promoting defecation | |
CN110169452A (zh) | 一种含变性淀粉的助消化酸奶及其制备方法 | |
CN106165897A (zh) | 通过酶解制备的猕猴桃营养粉及其应用 | |
CN109310718B (zh) | 上消化道内菌群改善剂 | |
CN109275714A (zh) | 一种解酒护肝酸奶及其制备方法 | |
CN103081997A (zh) | 一种营养酸奶及其制作方法 | |
CN108618125A (zh) | 手术后全营养配方食品 | |
CN105907598A (zh) | 一种猕猴桃醋及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180612 |